Research status and progression of third-line therapy for refractory metastatic colorectal cancer

doi:10.3877/cma.j.issn.2095-3224.2022.05.010

Abstract

Abstract:

Patients with metastatic colorectal cancer (mCRC) have poor prognoses, and selecting effective therapy in the third-line settings is still a challenge. To extend patient survival time, several novel oral agents, including regorafenib, trifluridine/tipiracil (TAS-102) and fruquintinib, have been gradually approved as standard therapy for refractory mCRC. More promising agents are under clinical research. In this review, we summarized the currently approved treatment and emerging treatment options for refractory mCRC, and also discussed if the treatment sequence of several different regimens would affect the survival benefit of refractory mCRC patients.

Key words: Colorectal neoplasms, Neoplasm metastasis, Refractory, Targeted therapy, Immunotherapy

Wenwei Yang, Yaru Niu, Yongkun Sun. Research status and progression of third-line therapy for refractory metastatic colorectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2022, 11(05): 415-419.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2022.05.010

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2022/V11/I05/415

Figures/Tables 1

References 39

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2]	Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019 [J]. CA Cancer J Clin, 2019, 69(5): 363-385.
[3]	Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest [J]. J Clin Oncol, 2007, 25(13): 1670-1676.
[4]	Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial [J]. JAMA, 2017, 317(23): 2392-2401.
[5]	Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial [J]. Lancet, 2013, 381(9863): 303-312.
[6]	Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer [J]. N Engl J Med, 2015, 372(20): 1909-1919.
[7]	Li J, Qin S, Xu RH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: The FRESCO randomized clinical trial [J]. JAMA, 2018, 319(24): 2486-2496.
[8]	Ettrich TJ, Seufferlein T. Regorafenib [J]. Recent Results Cancer Res, 2018, 211: 45-56.
[9]	Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet Oncol, 2015, 16(6): 619-629.
[10]	Nakashima M, Ide K, Kawakami K. Comparison of standard initial dose and reduced initial dose regorafenib for colorectal cancer patients: a retrospective cohort study [J]. Target Oncol, 2019, 14(3): 295-306.
[11]	Xu J, Kim TW, Shen L, et al. Results of a randomized, double-blind, placebo-controlled, phaseIII Trial of trifluridine/tipiracil (TAS-102) monotherapy in asian patients with previously treated metastatic colorectal cancer: the TERRA study [J]. J Clin Oncol, 2018, 36(4): 350-358.
[12]	Deng Y, Li X. Fruquintinib and its use in the treatment of metastatic colorectal cancer [J]. Future Oncol, 2019, 15(22): 2571-2576.
[13]	Shirley M. Fruquintinib: first global approval [J]. Drugs, 2018, 78(16): 1757-1761.
[14]	Dasari A, Sobrero A, Yao J, et al. FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer [J]. Future Oncol, 2021, 17(24): 3151-3162.
[15]	Lin B, Song X, Yang D, et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1 [J]. Gene, 2018, 654: 77-86.
[16]	Chi Y, Shu Y, Ba Y, et al. Anlotinib monotherapy for refractory metastatic colorectal cancer: a double-blinded, placebo-controlled, randomized phase Ⅲ trial (ALTER0703) [J]. Oncologist, 2021, 26(10): e1693-e1703.
[17]	Jonker DJ, O'callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer [J]. N Engl J Med, 2007, 357(20): 2040-2048.
[18]	Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J]. N Engl J Med, 2004, 351(4): 337-345.
[19]	Cremolini C, Rossini D, Dell'aquila E, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial [J]. JAMA Oncol, 2019, 5(3): 343-350.
[20]	Suenaga M, Mizunuma N, Matsusaka S, et al. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study [J]. Drug Des Devel Ther, 2015, 9: 3099-3108.
[21]	Costa T, Nuñez J, Felismino T, et al. REOX: Evaluation of the efficacy of retreatment with an oxaliplatin-containing regimen in metastatic colorectal cancer: a retrospective single-center study [J]. Clin Colorectal Cancer, 2017, 16(4): 316-323.
[22]	Yang Q, Huang Y, Jiang Z, et al. Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer [J]. Onco Targets Ther, 2018, 11: 2467-2473.
[23]	Briani C, Argyriou AA, Izquierdo C, et al. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study [J]. J Peripher Nerv Syst, 2014, 19(4): 299-306.
[24]	Pietrantonio F, Di Nicolantonio F, Schrock AB, et al. ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer [J]. J Natl Cancer Inst, 2017, 109(12).
[25]	Richman SD, Southward K, Chambers P, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3 256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials [J]. J Pathol, 2016, 238(4): 562-570.
[26]	Javle M, Borad MJ, Azad NS, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study [J]. Lancet Oncol, 2021, 22(9): 1290-1300.
[27]	Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial [J]. Lancet Oncol, 2016, 17(6): 738-746.
[28]	Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial [J]. Lancet Oncol, 2021, 22(6): 779-789.
[29]	Drosten M, Barbacid M. Targeting the MAPK pathway in KRAS-driven tumors [J]. Cancer Cell, 2020, 37(4): 543-550.
[30]	Ou SI, Jänne PA, Leal TA, et al. First-in-human phase I/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRAS(G12C) solid tumors (KRYSTAL-1) [J]. J Clin Oncol, 2022, 40(23): 2530-2538.
[31]	Yokota T, Ura T, Shibata N, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer [J]. Br J Cancer, 2011, 104(5): 856-862.
[32]	Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer [J]. N Engl J Med, 2019, 381(17): 1632-1643.
[33]	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in tumors with mismatch-repair deficiency [J]. N Engl J Med, 2015, 372(26): 2509-2520.
[34]	Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer [J]. J Clin Oncol, 2018, 36(8): 773-779.
[35]	Fukuoka S, Hara H, Takahashi N, et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603) [J]. J Clin Oncol, 2020, 38(18): 2053-2061.
[36]	Yoshida Y, Yamada T, Kamiyama H, et al. Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study [J]. Int J Clin Oncol, 2021, 26(1): 111-117.
[37]	Van Cutsem E, Danielewicz I, Saunders MP, et al. Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study [J]. Ann Oncol, 2020, 31(9): 1160-1168.
[38]	Shitara K, Yamanaka T, Denda T, et al. REVERCE: a randomized phase Ⅱ study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients [J]. Ann Oncol, 2019, 30(2): 259-265.
[39]	Tai CC, Chen WS, Jiang JK, et al. Comparing late-line treatment sequence of regorafenib and reduced-intensity FOLFOXIRI for Refractory metastatic colorectal cancer[J]. Am J Clin Oncol, 2020, 43(1): 28-34.

药物	作用机制	临床研究	研究分期	研究设计	OS（月）	PFS（月）	常见≥3级不良反应
瑞戈非尼	VEGFR1-3，TIE2，c-KIT，RET，RAF-1，BRAF，PDGFR，FGFR靶向药	CORRECT	Ⅲ期	瑞戈非尼 vs. 安慰剂	6.4 vs. 5.0	1.9 vs. 1.7	手足皮肤反应、高血压、乏力
瑞戈非尼	VEGFR1-3，TIE2，c-KIT，RET，RAF-1，BRAF，PDGFR，FGFR靶向药	CONCUR	Ⅲ期	瑞戈非尼 vs. 安慰剂	8.8 vs. 6.3	3.2 vs. 1.7	手足皮肤反应、高血压、乏力
TAS-102	化疗药	RECOURSE	Ⅲ期	TAS-102 vs. 安慰剂	7.1 vs. 5.3	2.0 vs. 1.7	中性粒细胞减少、白细胞减少、贫血
TAS-102	化疗药	TERRA	Ⅲ期	TAS-102 vs. 安慰剂	7.8 vs. 7.1	2.0 vs. 1.8	中性粒细胞减少、白细胞减少、贫血
呋喹替尼	VEGFR 1-3靶向药	FRESCO	Ⅲ期	呋喹替尼 vs. 安慰剂	9.3 vs. 6.6	3.7 vs. 1.8	高血压、手足皮肤反应、蛋白尿

药物	作用机制	临床研究	研究分期	研究设计	OS（月）	PFS（月）	常见≥3级不良反应
瑞戈非尼	VEGFR1-3，TIE2，c-KIT，RET，RAF-1，BRAF，PDGFR，FGFR靶向药	CORRECT	Ⅲ期	瑞戈非尼 vs. 安慰剂	6.4 vs. 5.0	1.9 vs. 1.7	手足皮肤反应、高血压、乏力
瑞戈非尼	VEGFR1-3，TIE2，c-KIT，RET，RAF-1，BRAF，PDGFR，FGFR靶向药	CONCUR	Ⅲ期	瑞戈非尼 vs. 安慰剂	8.8 vs. 6.3	3.2 vs. 1.7	手足皮肤反应、高血压、乏力
TAS-102	化疗药	RECOURSE	Ⅲ期	TAS-102 vs. 安慰剂	7.1 vs. 5.3	2.0 vs. 1.7	中性粒细胞减少、白细胞减少、贫血
TAS-102	化疗药	TERRA	Ⅲ期	TAS-102 vs. 安慰剂	7.8 vs. 7.1	2.0 vs. 1.8	中性粒细胞减少、白细胞减少、贫血
呋喹替尼	VEGFR 1-3靶向药	FRESCO	Ⅲ期	呋喹替尼 vs. 安慰剂	9.3 vs. 6.6	3.7 vs. 1.8	高血压、手足皮肤反应、蛋白尿

Please choose a citation manager

Content to export